Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human randomized placebo-controlled phase 1 study of oral GDC-8264 in healthy volunteers
NL-OMON55161Phase 1Completed
- Sponsor
- Genentech
- Start
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GDC-8264 in inflammatory bowel disease (IBD) (3 arms), sponsored by Genentech. Primary endpoint: Safety and tolerability of single and multiple doses of GDC-8264 compared with placebo. Started Dec 2019; status: completed.
02
Drugs
GDC-8264
03
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON55161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55161.